A

Amgen

Makes biotech medicines for serious illnesses

Director, Value Strategy & Marketing - Rare Disease & Oncology

Full-TimeUpdated on 10/24/2026
$208.3k - $281.8k
Mid, Senior
Bachelor's, Master's, MBA, PharmD, PhD
Thousand Oaks, CA, USA
Remote
Growth & MarketingProduct Marketing

About the job

Requirements
  • Doctorate degree and 4 years of commercial experience, or a master's degree and 7 years of commercial experience, or a bachelor's degree and 9 years of commercial experience.
  • At least 8 years of pharmaceutical or biotechnology industry experience, including significant U.S. market access, payer marketing, value strategy, or related Value & Access responsibility is preferred.
  • Demonstrated experience developing payer, value, reimbursement, or market access strategies for specialty pharmaceutical products is preferred; Rare Disease and/or Oncology experience is strongly preferred.
  • People leadership experience with the ability to coach, develop, and prioritize work across a high-performing team is preferred.
  • Strong understanding of U.S. payer decision making across medical and pharmacy benefits, including medical policy, utilization management, specialty distribution, site of care, and reimbursement for physician-administered therapies is preferred.
  • Launch and lifecycle-management experience, including anticipating future market dynamics and translating them into access implications, is preferred.
  • Ability to synthesize payer insights, clinical evidence, health economic evidence, and real-world data into differentiated value strategies and executive recommendations is preferred.
  • Experience influencing evidence-generation priorities and partnering effectively with HEOR, observational research, Medical, Brand, Market Access, and Coverage & Pricing teams is preferred.
  • Strong business acumen, strategic judgment, analytical capability, and ability to manage multiple complex workstreams in a matrixed environment are preferred.
  • Demonstrated aptitude for generative AI and emerging technologies, with the ability to apply them responsibly to improve strategic thinking, productivity, and organizational effectiveness, is preferred.
  • Strong executive communication and presentation skills are preferred.
Responsibilities
  • Lead portfolio value strategy across Rare Disease and Oncology, translating brand objectives, payer dynamics, competitive change, and access barriers into clear priorities and actionable strategies.
  • Define differentiated payer value propositions for priority assets and ensure clinical, economic, real-world, and population-level evidence is translated into credible customer value stories.
  • Guide U.S. payer-relevant evidence strategy with HEOR, CfOR, Medical, Brand, and Insights; identify evidence gaps and shape studies intended to defend coverage, improve quality of coverage, and support appropriate patient identification and treatment.
  • Ensure payer and reimbursement considerations are integrated early into launch, indication-expansion, and lifecycle planning, including medical-benefit, pharmacy-benefit, site-of-care, specialty distribution, and utilization-management dynamics.
  • Partner with Market Access and MVPH leadership to shape customer engagement priorities, prepare for high-value payer and health-system discussions, and translate field insights into broader portfolio actions.
  • Partner with Coverage & Pricing to ensure value strategy complements coverage, pricing, contracting, and reimbursement strategies while maintaining clear functional accountability.
  • Oversee development and deployment of payer value resources, including payer customer value aids (CVAs), economic tools, real-world evidence communications, health care economic information (HCEI) and pre-approval information exchange (PIE) resources where appropriate, payer FAQs, training, and customer-specific materials.
  • Lead, coach, and develop two Senior Managers; establish clear portfolio ownership, operating rhythms, and expectations for strategic thinking, cross-functional leadership, and executional excellence.
  • Champion AI-enabled ways of working across Value Strategy & Marketing, using approved AI tools to accelerate insight synthesis, evidence translation, strategic development, content creation, and team productivity.
  • Build AI capability across the team by identifying high-value use cases, encouraging responsible experimentation, sharing best practices, and ensuring adherence to company policies, privacy, compliance, and review requirements.
  • Manage portfolio budgets, agency relationships, and investment priorities; allocate resources to the highest-value strategic opportunities and establish measures of impact.
  • Communicate opportunities, risks, tradeoffs, and recommendations with clarity to senior leadership and drive alignment across a complex matrix.
Desired Qualifications
  • An advanced degree such as an MBA, MPH, PharmD, PhD, or another relevant graduate degree is preferred.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.